{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:08:41Z","timestamp":1793844521881,"version":"4.6.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejmech.2023.116038","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T19:02:36Z","timestamp":1702926156000},"page":"116038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Discovery and development of BI 1265162, an ENaC inhibitor for the treatment of cystic fibrosis"],"prefix":"10.1016","volume":"265","author":[{"given":"Bodo","family":"Betzemeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Heckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Linz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Veser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Wiedenmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5543-6387","authenticated-orcid":false,"given":"J\u00f6rg T.","family":"Kley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.116038_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/JEP.S255377","article-title":"Pharmacological modulation of ion channels for the treatment of cystic fibrosis","volume":"13","author":"Pinto","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116038_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102098","article-title":"Small-molecule drugs for cystic fibrosis: where are we now?","volume":"72","author":"Laselva","year":"2022","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.116038_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/jpet.107.130443","volume":"325","author":"Hirsh","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.116038_bib4","article-title":"3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL (2,3,4,5,6-PENTAHYDROXYHEXYL) amino) ethoxy) phenyl) butyl) CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE","author":"Johnson","year":"2013","journal-title":"PCT Patent Appl."},{"key":"10.1016\/j.ejmech.2023.116038_bib5","unstructured":"Cortellis Drug Report. Identifier: p-552-02, (n.d.). https:\/\/www.cortellis.com\/intelligence\/report\/ci\/nextgendrugall\/57894 (accessed August 30, 2023)."},{"key":"10.1016\/j.ejmech.2023.116038_bib6","unstructured":"Cortellis Drug Report. Identifier: idrevloride, (n.d.). https:\/\/www.cortellis.com\/intelligence\/report\/ci\/nextgendrugall\/83414 (accessed August 30, 2023)."},{"key":"10.1016\/j.ejmech.2023.116038_bib7","article-title":"Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial","author":"Ringshausen","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2023.116038_bib8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1517\/13543776.2013.829454","article-title":"Novel small molecule epithelial sodium channel inhibitors as potential therapeutics in cystic fibrosis \u2013 a patent evaluation","volume":"23","author":"Schoenberger","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.116038_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bmcl.2011.12.016","article-title":"Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines","volume":"22","author":"Hunt","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.116038_bib10","series-title":"ENAC BLOCKERS, PCT Patent Application","author":"Ibrahim","year":"2011"},{"key":"10.1016\/j.ejmech.2023.116038_bib11","first-page":"145","article-title":"Development of Respimat\u00ae soft MistTM inhaler and its clinical utility in respiratory disorders","volume":"4","author":"Dalby","year":"2011","journal-title":"M\u00e9d. Devices (Auckl., NZ)."},{"key":"10.1016\/j.ejmech.2023.116038_bib12","doi-asserted-by":"crossref","first-page":"C162","DOI":"10.1152\/ajpcell.00459.2010","article-title":"Methods for stable recording of short-circuit current in a Na+-transporting epithelium","volume":"301","author":"Gondzik","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2023.116038_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1165\/rcmb.4869","article-title":"Characterization of ion and fluid transport in human bronchioles","volume":"27","author":"Blouquit","year":"2002","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.116038_bib14","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1021\/jm00087a022","article-title":"Molecular recognition of amiloride analogs: a molecular electrostatic potential analysis. 1. Pyrazine ring modifications","volume":"35","author":"Venanzi","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116038_bib15","series-title":"HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF, US 2013\/0157981 A1","author":"Heckel","year":"2013"},{"key":"10.1016\/j.ejmech.2023.116038_bib16","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1016\/j.bmcl.2015.07.015","article-title":"Discovery of highly potent, lung-localized epithelial sodium channel inhibitors","volume":"25","author":"Kumar","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.116038_bib17","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/jps.10169","article-title":"Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility","volume":"91","author":"Zhou","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2023.116038_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/17425255.2020.1777280","article-title":"Soft drugs: design principles, success stories, and future perspectives","volume":"16","author":"Buchwald","year":"2020","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2023.116038_bib19","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2174\/0929867054864840","article-title":"Antedrugs: an approach to safer drugs","volume":"12","author":"Khan","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116038_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.clinthera.2005.04.006","article-title":"Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease","volume":"27","author":"Koumis","year":"2005","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2023.116038_bib21","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1021\/cr9601019","article-title":"Lipophilicity profiles of ampholytes","volume":"97","author":"Pagliara","year":"1997","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.116038_bib22","first-page":"114","article-title":"Laws governing the dissociation of dialkylphosphoric, -phosphonic and -phosphinic acids in water and in aqueous ethanol","volume":"318","author":"Galkin","year":"1991","journal-title":"Dokl. Chem."},{"key":"10.1016\/j.ejmech.2023.116038_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00429-2020","article-title":"Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis","volume":"6","author":"Nickolaus","year":"2020","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ejmech.2023.116038_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.770375","article-title":"Aldosterone-regulated sodium transport and blood pressure","volume":"13","author":"Tsilosani","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejmech.2023.116038_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116038_bib26","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.2174\/092986709788803213","article-title":"Medicinal chemistry strategies to minimize phospholipidosis","volume":"16","author":"Ratcliffe","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116038_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/d41573-022-00071-9","article-title":"opnMe.com: a digital initiative for sharing tools with the biomedical research community","volume":"21","author":"Gollner","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.116038_bib28","unstructured":"opnMe Boehringer Ingelheim Open Innovation Portal. ENaC Inhibitor BI-8668, (n.d.). https:\/\/www.opnme.com\/molecules\/enac-inhibitor-bi-8668 (accessed August 30, 2023) . ."},{"key":"10.1016\/j.ejmech.2023.116038_bib29","first-page":"48","article-title":"Are high potency active pharmaceutical ingredients (HPAPI) also high risks for cross-contamination?","volume":"35","author":"Barle","year":"1997","journal-title":"Chim. Oggi - Chem. Today"},{"key":"10.1016\/j.ejmech.2023.116038_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00447-2020","article-title":"First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers","volume":"7","author":"Mackie","year":"2021","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ejmech.2023.116038_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00746-2021","article-title":"Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study","volume":"59","author":"Goss","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2023.116038_bib32","series-title":"APEX2","author":"Bruker","year":"2012"},{"key":"10.1016\/j.ejmech.2023.116038_bib33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2 : a complete structure solution, refinement and analysis program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2023.116038_bib34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1107\/S0021889807010941","article-title":"IL MILIONE: a suite of computer programs for crystal structure solution of proteins","volume":"40","author":"Burla","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2023.116038_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1107\/S2053273314022207","article-title":"The anatomy of a comprehensive constrained, restrained refinement program for the modern computing environment \u2013 olex2 dissected","volume":"71","author":"Bourhis","year":"2015","journal-title":"Acta Crystallogr., Sect. A: Found. Adv."},{"key":"10.1016\/j.ejmech.2023.116038_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0021-9673(02)00064-X","article-title":"Method for measuring the logarithm of the octanol\u2013water partition coefficient by using short octadecyl\u2013poly(vinyl alcohol) high-performance liquid chromatography columns","volume":"952","author":"Donovan","year":"2002","journal-title":"J. Chromatogr., A"},{"key":"10.1016\/j.ejmech.2023.116038_bib37","series-title":"Drug Discovery and Development - Present and Future","first-page":"169","article-title":"The use of in vitro 3D cell models in drug development for respiratory diseases","author":"Huang","year":"2011"},{"key":"10.1016\/j.ejmech.2023.116038_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/toxsci\/55.1.24","article-title":"Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations","volume":"55","author":"Driscoll","year":"2000","journal-title":"Toxicol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342301005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342301005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T09:46:30Z","timestamp":1736847990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342301005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":38,"alternative-id":["S022352342301005X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116038","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and development of BI 1265162, an ENaC inhibitor for the treatment of cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116038"}}